Updates to the label for Elmiron®, a medication used to treat bladder pain and inflammation, now warn of potential, permanent damage to the retina that could cause irreversible vision loss.
The U.S. Food and Drug Administration sent a warning letter to Allergan, now AbbVie, reprimanding the medical device manufacturer for serious deficiencies in Allergan’s post-approval studies of its recalled breast implants, which have been linked to an increased risk of cancer.
Recent changes to New Jersey state law in May 2019 that broadened the statute of limitations, or the time in which a person can file a claim, for civil childhood sexual abuse claims are constitutional, Morris County’s Superior Court Judge Paul Bogaard ruled.
Johnson & Johnson announced it will cease production of its talc-based baby powder products in the U.S. and Canada amid thousands of lawsuits alleging the product contains asbestos and caused cancer. Products will continue to be sold by retailers until supplies run out.
New York extended its deadline to file civil sexual abuse claims under the state’s Child Victims Act to Aug. 14, 2021 due to COVID-19.
Litigation concerning claims that the popular antacid medication Zantac causes cancer continues to move forward with U.S. District Judge Robin Rosenberg on May 8, 2020, appointing attorneys to lead the multidistrict litigation, a national consolidation of individual cases.
Eleven Motley Rice attorneys were selected as a 2020 Super Lawyers® or Rising Stars for South Carolina, Washington, D.C., and West Virginia. Super Lawyers recognition represents no more than 5 percent of attorneys in each state and the Rising Stars list makes up no more than 2.5 percent of attorneys in a state.
Thousands of women who allege Johnson & Johnson’s talc-based baby powder caused their ovarian cancer can move forward with claims against the company, a federal judge ruled on April 27.
Recalls involving the name-brand heartburn drug Zantac (ranitidine) and similar generic versions culminated April 1 in the FDA asking drug manufacturers to immediately withdraw all prescription and over-the-counter ranitidine products, including generic ones, from the U.S. market due to concerns that they may contain toxic N-Nitrosodimethylamine (NDMA).
Motley Rice, as co-lead and trial counsel for end-payor plaintiffs, helped reach a $62.5 million class action settlement to resolve claims alleging pharmaceutical drug manufacturers engaged in anticompetitive conduct to delay market entry of generic Loestrin 24 FE.